AstraZeneca, SWIBCo Launch Stem Cell Cardiovascular Therapy Collaboration

AstraZeneca will develop novel cardiovascular and catheter-based therapies using Procella Therapeutics’ stem cell technology and Smartwise’s catheter injection method, it was disclosed today, through a collaboration that could generate up to $320 million-plus for the parent company of the pharma giant’s partners.Procella and Smartwise are wholly owned subsidiaries of SWIB Holdings, which announced the collaboration. SWIB Holdings is the holding company of Swedish Innovation Bri